Hematology, transfusion and cell therapy最新文献

{"title":"Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation.","authors":"Moazzam Shahzad, Muhammad Kashif Amin, Maggie Nelson, Abhinav Vyas, Joe S Al-Ramahi, Nausheen Ahmed, Rajat Bansal, Haitham Abdelhakim, Leyla Shune, Al-Ola Abdallah, Anurag K Singh, Sunil H Abhyankar, Joseph P McGuirk, Muhammad Umair Mushtaq","doi":"10.1016/j.htct.2025.103961","DOIUrl":"10.1016/j.htct.2025.103961","url":null,"abstract":"<p><strong>Background: </strong>Severe refractory alloimmune thrombocytopenia is a challenging and life-threatening complication in patients with hematologic disorders who are undergoing allogeneic hematopoietic stem cell transplantation. This study aimed to investigate the utility of continuous intravenous immunoglobulin and platelet transfusions as a therapeutic approach for alloimmune thrombocytopenia in patients undergoing allogeneic transplants.</p><p><strong>Methods: </strong>A single-center retrospective analysis was conducted of ten adult allogeneic transplant patients hospitalized with transfusion-refractory alloimmune thrombocytopenia. Intravenous immunoglobulin (2 g/kg) was administered as a slow continuous infusion over 48 h along with a continuous apheresis platelet infusion (one apheresis unit over eight hours). Clinical response was defined as the resolution of bleeding or patients being able to undergo the required procedure without bleeding complications.</p><p><strong>Results: </strong>The median time after the transplant was 27.5 (range: 7-299) days. Myeloablative and reduced-intensity conditioning were performed in 5 (50 %) and 5 (50 %) patients, respectively. The median platelet count at the time of infusion was 4.5 × 10⁹/L. All patients were able to achieve clinical response with the median maximum platelet count within ten days of the infusion being 41.0 × 10⁹/L. The median time to best response was three days with a median platelet count of 27.0 × 10⁹/L.</p><p><strong>Conclusions: </strong>Continuous intravenous immunoglobulin and platelet infusions over 48 h may be able to overcome life-threatening refractory alloimmune thrombocytopenia in transplant patients and may provide a bridging measure until platelet engraftment or for life-threatening hemorrhage or invasive procedures with high bleeding risk.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"47 4","pages":"103961"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The battle against pediatric retinoblastoma: insights from 2024 medical literature.","authors":"Yoshiyasu Takefuji","doi":"10.1016/j.htct.2025.103839","DOIUrl":"10.1016/j.htct.2025.103839","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"47 4","pages":"103839"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of hydroxyurea on tubular phosphate handling in sickle cell nephropathy","authors":"Gabriela Araujo de Abreu, Duaran Lopes de Sousa, Suzzy Maria Carvalho Dantas, Alice Maria Costa Martins, T. L. Sampaio, R. Lemes","doi":"10.1016/j.htct.2023.11.015","DOIUrl":"https://doi.org/10.1016/j.htct.2023.11.015","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"16 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139818365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemorrhagic code protocol, a successful case in the patient blood management model for patients with severe hemorrhages","authors":"João Carlos de Campos Guerra, Michele Jaures, Roseny dos Reis Rodrigues, A. Cypriano, D. Malheiro, Anna Carolina Batista Dantas, Fernanda Paulino Fernandes, Neila Maria Marques Negrini, V. Teich","doi":"10.1016/j.htct.2024.01.002","DOIUrl":"https://doi.org/10.1016/j.htct.2024.01.002","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"34 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies","authors":"Soumya Pandey, Akul Shrivastava, Y. Harville, Michele Cottler-Fox, T. Harville","doi":"10.1016/j.htct.2023.11.016","DOIUrl":"https://doi.org/10.1016/j.htct.2023.11.016","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"31 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139888795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-PF4 antibodies and their relationship with COVID infection","authors":"Chieh Yang, Irene Wang, Akshit Chitkara, Jibin Swankutty, Rushin Patel, Samir V Kubba","doi":"10.1016/j.htct.2023.11.012","DOIUrl":"https://doi.org/10.1016/j.htct.2023.11.012","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"31 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139892698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, patient journey and unmet needs related to hemophilia in Brazil: a scoping review with evidence map","authors":"N. B. Schneider, C. L. P. de Araujo, Harryson Wings Godoy dos Santos, Simone Lima, Maicon Falavigna, D. Pachito","doi":"10.1016/j.htct.2023.12.004","DOIUrl":"https://doi.org/10.1016/j.htct.2023.12.004","url":null,"abstract":"","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":"525 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139831674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of C-reactive protein and its prognostic relationship in patients with Hodgkin's Lymphoma.","authors":"Elizete Aparecida da Silva Negreiros, Talita Máira Bueno da Silveira, Sérgio Costa Fortier, Carlos Sérgio Chiattone","doi":"10.1016/j.htct.2023.11.011","DOIUrl":"https://doi.org/10.1016/j.htct.2023.11.011","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the prognostic value of C-Reactive Protein (CRP), at diagnosis and during follow-up, of patients with Hodgkin´s Lymphoma treated at the Hematology Service of the Santa Casa de São Paulo Hospital, and to correlate serum CRP levels with disease stage and treatment response.</p><p><strong>Methods: </strong>A retrospective study involving review of 71 medical records of patients diagnosed with Hodgkin´s Lymphoma between February 2012 and January 2016 was performed. Three patients were subsequently excluded, giving a total of 68 patients for analysis. A level of CRP > 1mg/dl was considered elevated.</p><p><strong>Results: </strong>Patients were predominantly male (61.8%) and mean age was 34 years. Fifty-three (78%) patients had advanced stage and (76.5%) had B symptoms. Elevated baseline CRP was associated with greater likelihood of B symptoms (p= 0.02) and of advanced stage (p= 0.015). Patients with Low CRP level after 5th and 6th cycles of chemotherapy was associated with complete response (p=0.04 and p=0.03, respectively). Treatment-refractory patients had greater risk of death (p=0.002).</p><p><strong>Conclusion: </strong>CRP is clinically important for follow-up of patients with Hodgkin´s Lymphoma, where high levels were associated with advanced disease and/or presence of B symptoms. CRP level was considered a predictor of treatment response. Persistence of high CRP values during treatment was associated with refractoriness.</p>","PeriodicalId":94026,"journal":{"name":"Hematology, transfusion and cell therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}